Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Monday, down -4.77% from the previous trading day, before settling in for the closing price of $19.3. Over the past 52 weeks, NRIX has traded in a range of $8.18-$22.50.
Healthcare Sector giant saw their annual sales slid by -38.86% over the last five years. While this was happening, its average annual earnings per share was recorded -5.67%. With a float of $99.81 million, this company’s outstanding shares have now reached $101.37 million.
Nurix Therapeutics Inc (NRIX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.53%, while institutional ownership is 82.83%. The most recent insider transaction that took place on Dec 18 ’25, was worth 67,314. In this transaction Chief Legal Officer of this company sold 3,760 shares at a rate of $17.90, taking the stock ownership to the 50,897 shares. Before that another transaction happened on Dec 18 ’25, when Company’s Officer proposed sale 7,520 for $18.21, making the entire transaction worth $136,939.
Nurix Therapeutics Inc (NRIX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 11/30/2024, the organization reported -0.75 earnings per share (EPS), lower than consensus estimate (set at -0.67) by -0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.36% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -3.33 in one year’s time.
